Journal of Clinical Oncology, 2009 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 27, No 15S (May 20 Supplement), 2009: LBA5510
© 2009 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Herrstedt, J. Articles by du Bois, A. Search for Related Content PubMed Articles by Herrstedt, J. Articles by du Bois, A.

Abstract

A randomized, phase III study (AGO-OVAR-9, GINECO-TCG, NSGO-OC-0102): Gemcitabine-paclitaxel-carboplatin versus paclitaxel-carboplatin as first-line treatment of ovarian cancer (OC): Survival of FIGO stage I-IIA patients

Odense University Hospital, Odense, Denmark; University of Tuebingen, Tuebingen, Germany; Centre Hospitalier, La Roche sur Yon, France; Philipps University, Marburg, Germany; The Norwegian Radium Hospital, Oslo, Norway; University Hospital Ulm, Ulm, Germany; Ubbo-Emmius-Klinik gGmbH, Aurich, Germany; St. Vincentius-Krankenhäuser, Karlsruhe, Germany; Centre Léon Bérard, Lyon, France; HSK, Dr. Horst Schmidt Klinik GmbH, Wiesbaden, Germany

LBA5510

The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology.

Author Disclosure

Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly Merck

Abstract presentation from the 2009 ASCO Annual Meeting